Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Ott

Pulmonary Disease Eglin Afb, FL Medical Doctor

NPI 1629052725 CMS profile 28847

307 Boatner Rd Ste 114, Eglin Afb, FL 32542

Open in the dashboard

General payments

$909,084

1,110 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Ott of Eglin Afb, FL is reported in the CMS Open Payments database as having received $909,084 across 1,110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,032 203
2024 General $116,431 156
2023 General $189,249 272
2022 General $132,096 140
2021 General $119,397 126
2020 General $88,832 87
2019 General $116,047 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Ott
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Ott were reported at $147,032. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Ott Pulmonary Disease median Middle half National median
2019 $116,047 $377 $109–$1,340 $163
2020 $88,832 $230 $56–$907 $114
2021 $119,397 $269 $68–$1,072 $132
2022 $132,096 $390 $100–$1,457 $149
2023 $189,249 $419 $114–$1,659 $160
2024 $116,431 $476 $123–$1,818 $164
2025 $147,032 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $902,783 1,079 payments
  2. Grifols USA, LLC $5,102 6 payments
  3. ViiV Healthcare Company $600 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $345 11 payments
  5. Vapotherm Inc $101 4 payments
  6. Inspire Medical Systems, Inc. $34 2 payments
  7. Gilead Sciences, Inc. $30 2 payments
  8. Regeneron Healthcare Solutions, Inc. $21 1 payment
  9. Biohaven Pharmaceutical Holding Company Ltd. $20 1 payment
  10. Merck Sharp & Dohme Corporation $18 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $732,963 254 payments
  2. Travel and Lodging $145,252 490 payments
  3. Food and Beverage $20,802 360 payments
  4. Consulting Fee $9,450 3 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $600 1 payment
  6. Gift $17 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $321,161 338 payments
  2. NUCALA Immunology $192,564 242 payments
  3. AREXVY Respiratory $157,988 208 payments
  4. NUCALA Respiratory $48,529 44 payments
  5. ANORO ELLIPTA $17,804 21 payments
  6. AREXVY Respiratory $14,168 17 payments
  7. ANORO $9,770 6 payments
  8. Prolastin-C Liquid $5,102 6 payments
  9. OFEV $138 6 payments
  10. Precision Flow $101 4 payments
  11. Other $299 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record